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What’s known on this subject: 68 
Failure to identify serious infections in children results in adverse outcomes whilst a failure to 69 
rule-out serious infections results in unnecessary antibiotic use and hospital admission. 70 
Multivariable clinical risk prediction models appear to discriminate well between serious and 71 
self-limiting infections. 72 
What this study adds: 73 
In a study of 1101 children of all ages, risk prediction models discriminated well between 74 
pneumonia, other serious bacterial infections and none. A published model performed well on 75 
external validation and model extension with Procalcitonin and Resistin improved 76 
discrimination. 77 
 78 
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ABSTRACT 111 
Background 112 
Improving the diagnosis of serious bacterial infections (SBI) in the children’s Emergency 113 
Department (ED) is a clinical priority. Early recognition reduces morbidity and mortality, 114 
while supporting clinicians to rule out SBI may limit unnecessary admissions and antibiotic 115 
use. 116 
Methods 117 
A prospective diagnostic accuracy study of clinical and biomarker variables for the diagnosis 118 
of SBI (pneumonia or ‘other SBI’) in febrile children <16 years. A diagnostic model was 119 
derived using multinomial logistic regression, and internally validated. External validation of 120 
a published model was undertaken followed by model updating and extension by the 121 
inclusion of Procalcitonin and Resistin. 122 
Results 123 
1101 children were studied, of whom 264 had SBI. A diagnostic model discriminated well 124 
between pneumonia and no SBI (c statistic 0.84, 95%CI 0.78 to 0.90) and between other SBIs 125 
and no SBI (0.77, 95% CI 0.71 to 0.83) on internal validation. A published multivariable 126 
model discriminated well on external validation. Model updating yielded good calibration 127 
with good performance at both high risk (Positive Likelihood Ratios 6.46 and 5.13 for 128 
pneumonia and other SBI respectively) and low risk (Negative Likelihood Ratios 0.16 and 129 
0.13) thresholds. Extending the model with the addition of Procalcitonin and Resistin yielded 130 
improvements in discrimination. 131 
Conclusions 132 
Diagnostic models discriminated well between pneumonia, other SBIs and no SBI in febrile 133 
children in the ED. Improvements in classification of non-events have the potential to reduce 134 
unnecessary hospital admission, and improve antibiotic prescribing. The benefits of this 135 
improved risk prediction should be further evaluated in robust impact studies.  136 
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INTRODUCTION 137 
Acute febrile illness is among the most common of all presentations to the children’s 138 
Emergency Department (ED).1 In this context, the probability of serious bacterial infection 139 
(SBI) is estimated to be 7% - predominantly lower respiratory or urinary tract infection.2  140 
The prompt recognition of SBI is fundamental to effective management. Children with 141 
meningococcal disease are frequently missed at initial presentation,3 and delayed recognition 142 
increases mortality.4, 5 Though rates of invasive infection have declined with the introduction 143 
of conjugate vaccines,6-8 SBI remains an important contributor to childhood morbidity and 144 
mortality.9  145 
In the UK, as rates of invasive infections have declined, the number  of children admitted to 146 
hospital has increased.10 The greatest increase is in young children with uncomplicated 147 
admissions for acute infections.11 Supporting clinicians to rule out SBI may reduce 148 
unnecessary hospital admissions in children.12  149 
A number of studies have reported the diagnostic accuracy of clinical13 and laboratory14 150 
variables in febrile children. More recently, risk prediction models combining clinical 151 
variables have been evaluated,2, 15 and in one the addition of CRP improved diagnostic 152 
accuracy.16 We ourselves have previously reported the combined performance of 153 
Procalcitonin, Resistin and Neutrophil Gelatinase-associated Lipocalin (NGAL) in Malawian 154 
children.17  155 
Diagnostic accuracy studies in febrile children have so far failed to impact clinical practice. 156 
Restrictive inclusion criteria, such as age, temperature, or clinical syndrome18 have limited 157 
their external validity and few have progressed to validation in external populations. We 158 
therefore set out to derive and internally validate a multivariable risk prediction model, and to 159 
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externally validate a previously published model16 for the diagnosis of SBI in febrile children 160 
of all ages. 161 
 162 
METHODS 163 
A prospective diagnostic accuracy study of clinical and biomarker variables for the diagnosis 164 
of SBI in children presenting to the Alder Hey Children’s Hospital ED. This is the busiest 165 
children’s ED in the UK, managing 60000 attendances each year. Recruitment was 166 
undertaken between November 2010 and April 2012. The study is reported in line with the 167 
Standards for Reporting of Diagnostic Accuracy (STARD) and Transparent Reporting of a 168 
multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) 169 
guidelines.19, 20 170 
Participants 171 
Children less than 16 years of age with fever (>38°C) or history of fever were eligible if they 172 
required blood tests as part of clinical management. Children with primary immunodeficiency 173 
were excluded. Using prior estimates of sensitivity and specificity of 65% and 90% 174 
respectively, and a rate of SBI of 15%, a sample size of 2300 was proposed. For skin and soft 175 
tissue infections, the reference standard for SBI was that children were deemed by the clinical 176 
team to require intravenous antibiotics. As the outcome diagnosis was solely based upon a 177 
clinical decision, and as this was true of all such cases, these children (n=82) were excluded 178 
(Figure 1). 179 
Patient involvement 180 
The GenerationR Young Person’s Advisory Group (www.generationr.org.uk), initiated by the 181 
National Institute for Health Research (NIHR) helped design patient information leaflets for 182 
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young people and families. In the course of the study  the group explored improvements in 183 
the recognition of serious infection, and the  discussed diagnostic tests using  various samples 184 
(such as saliva or blood). This involvement has informed the design of subsequent studies.  185 
Data 186 
Relevant clinical and biomarker variables were identified from the literature, including two 187 
large systematic reviews.13, 14 Clinical data were entered onto a proforma at  the time of the 188 
clinical assessment. Where possible, this was done by the attending clinician. When the 189 
proforma was incomplete, missing clinical information was retrieved from the clinical notes, 190 
where explicitly referenced. Paper proformas were collected by the study team daily. All 191 
proformas were cross checked against the clinical notes which were electronically scanned 192 
and stored. Missing or ambiguous data were recorded as missing. Data collection and entry 193 
into the database was blinded to final outcomes.  194 
Samples 195 
Tests performed in study subjects are recorded in supplementary Table 1. All samples were 196 
processed in Clinical Pathology Accredited laboratories. Blood (0.5 to 1ml) inoculated into 197 
culture bottles was monitored using the BacT/ALERT 3D system. Positive cultures were 198 
processed in line with UK standards for Microbiology investigations developed by Public 199 
Health England.21 Specific Streptococcus pneumoniae and Neisseria meningitidis PCR assays 200 
were performed at the Meningococcal Reference Unit in Manchester.22, 23 Urine and CSF 201 
underwent microscopy and culture on agar gel plates, and were processed in line with UK 202 
standards. Multiplex PCR was performed on respiratory (RSV, Influenza A and B, 203 
Parainfluenza 1-3, Adenovirus, Rhinovirus and Human Metapneumovirus) and CSF (HSV 1 204 
and 2, Varicella Zoster and Enterovirus) samples at the regional laboratory in Manchester. 205 
From April 2011, respiratory PCRs were performed using the FilmArray respiratory viral 206 
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panel (Biomerieux) and additionally identified Parainfluenza 4, Rhino/Enterovirus and 207 
Coronavirus 1-4. 208 
Blood (0.5-1ml) was collected into Lithium Heparin and plasma stored in Sarstedt microtubes 209 
at -80°C within 1 hour. Prior to analysis samples were thawed, vortex mixed and centrifuged 210 
to remove bubbles and particulate matter. Procalcitonin analysis was undertaken on the 211 
B.R.A.H.M.S. Kryptor according to manufacturer’s instructions. Quality control samples 212 
were analysed with each run. NGAL and Resistin were analysed using validated commercial 213 
ELISA.  214 
Reference tests 215 
In common with other published studies, outcome diagnoses were determined by a composite 216 
reference standard incorporating clinical, microbiological and radiological features 217 
(supplementary Table 2).14, 15, 24, 25 Using these pre-defined criteria, a paediatric research 218 
fellow and a paediatric infectious disease consultant independently attributed outcome 219 
diagnosis. In the case of disagreement, a second paediatric infectious disease consultant 220 
determined final outcome. Children who failed to meet the pre-defined criteria for SBI were 221 
considered to have ‘No SBI’. Subjects were followed up to 28 days to reduce 222 
misclassification.  223 
Statistical methods 224 
Analysis was undertaken in R, version 3.0.1.26 Missing data were handled by ten-fold 225 
multiple imputation using fully conditional specification implemented by the MICE 226 
package.27 In this method, missing values are replaced by values drawn from a conditional 227 
distribution specific to each individual predictor variable and defined by its own imputation 228 
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model. Data were assumed to be ‘missing at random’. The proportion of missing data relating 229 
to each clinical variable is recorded in supplementary table 3. 230 
Model derivation, validation and updating 231 
The dataset was randomised into a split sample “derivation”, and “validation” set. Univariate 232 
analysis of clinical and biomarker variables was undertaken using logistic regression, for the 233 
outcome of SBI. Explanatory variables were examined for evidence of collinearity. Scatter 234 
plots and generalised additive model (GAM) plots,28 fitted using the gam() function in the 235 
mgcv package, were examined for evidence of non-linearity on the log-odds scale. Piecewise 236 
and polynomial transformations were undertaken where appropriate. Plausible interaction 237 
terms were explored, including interactions between age,  heart rate and respiratory rate. A 238 
multivariable model was derived using a forwards stepwise method. Improvements in model 239 
fit were tested by means of a likelihood ratio test (α=0.05) and variables associated with a 240 
significant improvement were retained. Having identified a parsimonious model for SBI, 241 
these variables were then included in a multinomial regression model for the categorical 242 
outcomes “pneumonia”, “other SBI”, and “no SBI”.  243 
External validation of the model published by Nijman et al16 was undertaken using the 244 
published coefficients. A comparison of study participants is given in supplementary table 4. 245 
The model was updated by re-fitting variables and estimating the individual co-efficients, 246 
then extended by the inclusion of Procalcitonin and Resistin. This strategy preserved the 247 
original model structure and avoided deriving an entirely new model. The biomarkers were 248 
chosen having observed their value in our earlier model derivation. Additional clinical 249 
variables were not investigated as they appeared less predictive in our model derivation, and 250 
plausible clinical variables were adequately represented by the published model. 251 
Model evaluation 252 
10 
 
Performance characteristics of the fitted models at various risk thresholds were estimated 253 
using the epiR package.29 Discrimination was measured using the concordance (c) statistic, 254 
and illustrated by Receiver Operating Characteristic (ROC) curves using the pROC 255 
package.30 The c statistic estimates the probability that a randomly selected subject with the 256 
outcome of interest has a higher predicted probability than a randomly selected subject 257 
without. Comparison of the c statistic was undertaken using the DeLong method.31 For the 258 
multinomial regression model, the c statistic estimated discrimination between pairs of 259 
patients –a patient with pneumonia and a patient with no SBI, or patient with “other SBI” and 260 
a patient with no SBI. Confidence intervals (95%) were estimated by a bootstrapping process 261 
using 2000 bootstrap replicates. Calibration of the models (how closely risk predictions fit 262 
observed cases) was illustrated using multinomial calibration plots.32  263 
In the absence of established methods to report classification in multinomial risk prediction 264 
models, we compared crude classification (that is, the most likely diagnosis predicted by the 265 
multinomial models) in the updated and extended models. To investigate potential clinical 266 
utility, we estimated the ability of the models to ‘rule-out’ SBI (predictions for both 267 
categories of SBI <5%), or to ‘rule-in’ SBI (prediction of either category >20%). These 268 
thresholds represent approximately half and double the observed event rate in the study 269 
population. 270 
 271 
Ethics 272 
Approval for the study was granted by the Greater Manchester West Research Ethics 273 
Committee (10/H1014/53), and by the Alder Hey Children’s Hospital R&D department. 274 
 275 
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RESULTS 276 
Between 1st November 2010 and 3rd April 2012, 7949 children presented to the Alder Hey 277 
Children’s ED with fever. Of these, 1872 were eligible for inclusion, and 1101 recruited to 278 
the study (Figure 1). Median age was 2.4 years (IQR 0.9-5.7 years), and 55% were boys. 279 
Approximately one third of children had significant comorbidities (Table 1). 264 children 280 
(24.0%) were diagnosed with SBI (supplementary figure 1). 281 
The probability of pneumonia and other SBIs increased linearly with heart rate, respiratory 282 
rate and temperature. Consistent with other studies, increased work of breathing (odds ratio  283 
10.4, 95% confidence interval 6.69 to 16.2), hypoxia (9.29, 95%CI 5.35 to 16.1), and other 284 
respiratory variables were significantly associated with pneumonia. These features reduced 285 
the probability of other SBIs. Neck stiffness , a bulging fontanelle, irritability and dysuria 286 
were associated with other SBIs. Prolonged capillary refill time was associated with other 287 
SBIs (1.43, 95%CI 1.05 to 1.97) but not pneumoniawhile the presence of a rash reduced the 288 
probability of both pneumonia and other SBIs. Univariate odds ratios are presented in 289 
supplementary figure 2. CRP, Procalcitonin, NGAL and Resistin were all associated with SBI 290 
(supplementary table 5). 291 
Model derivation and internal validation  292 
The derived model included the variables “Respiratory rate”, and “Normal Air Entry” 293 
alongside CRP, PCT, and Resistin (supplementary table 6). Fitting CRP as a piecewise term 294 
improved the model fit. The model discriminated well on internal validation (c statistic 0.84, 295 
95%CI 0.78 to 0.90 for pneumonia, and 0.77, 95%CI 0.71 to 0.83 for other SBIs). Calibration 296 
plots suggested that the model overestimated the risk of pneumonia (Figure 2). 297 
 298 
12 
 
External validation and updating of Nijman model 299 
The published model of Nijman et al was validated in the complete dataset (n=1101). Using 300 
the published coefficients, the model discriminated well between pneumonia and no SBI, 301 
though less well between other SBIs and no SBI (c statistic 0.85 and 0.76 respectively, 302 
supplementary figure 3). Model calibration was poor though calibration plots indicated that 303 
predicted risks and observed outcomes were highly correlated (Figure 3). 304 
Observing the correlation between predicted probabilities and observed outcomes in the 305 
poorly calibrated model, we updated the model by re-estimating the individual co-efficients. 306 
No attempt was made to adjust the functional form of predictor variables. The re-fitted model 307 
discriminated well (c statistic 0.88 and 0.82 for pneumonia and other SBIs respectively), and 308 
was well calibrated (Figure 4).The model was then extended by the inclusion of PCT and 309 
Resistin. This improved discrimination of the pneumonia (c statistic increased from 0.88 to 310 
0.90, p=0.03), and other SBI models (from 0.82 to 0.84, p=0.03) and calibration remained 311 
good (supplementary figure 4). 312 
The performance characteristics of the updated and extended models are summarised in Table 313 
2. At a low-risk threshold of 5%, the extended pneumonia model had a sensitivity of 92% 314 
(95%CI 85 to 96%) and negative likelihood ratio (NLR) of 0.12 (0.06 to 0.23). For other 315 
SBIs, model sensitivity was 92% (86 to 95%), and NLR 0.21 (0.12 to 0.35). At a high-risk 316 
threshold (>20%), specificity was 89% (95%CI 87 to 91%) for pneumonia, with a positive 317 
likelihood ratio (PLR) of 6.69 (5.30 to 8.44), and 86% (83 to 88%), PLR of 4.96 (4.07 to 318 
6.03) for other SBIs.  319 
 320 
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Classification (determined by likeliest outcome category) was similar between the updated 321 
and extended models (893/1101 v 917/1101, 2.2% improvement, 95%CI -1.1 to 5.4%, 322 
supplementary Table 7). Using the extended model, SBI was correctly ‘ruled out’ in 31 323 
additional children (3.7%, 95%CI -1.0 to 8.4%) and there were five fewer potentially missed 324 
SBI diagnoses (14/264 v 19/264, 1.8% reduction, 95%CI -2.6 to 6.4%, Table 3). 325 
 326 
DISCUSSION 327 
Main findings 328 
In this large, prospective study of febrile children of all ages presenting to the ED, 329 
multinomial risk prediction models discriminated well between pneumonia, other SBIs and 330 
none. A newly derived model performed well on internal validation, and identified 331 
Procalcitonin and Resistin along with CRP as biomarkers of potential value. A published 332 
model performed well on external validation and the addition of PCT and Resistin improved 333 
discrimination. At a low-risk threshold (<5%), a NLR of 0.12 (pneumonia) or 0.21 (other 334 
SBIs) may help to rule out SBI, whilst at a high-risk threshold (>20%) PLRs of 6.69 and 4.96 335 
may expedite treatment. 336 
 337 
Strengths: 338 
We present data on multiple biomarkers of SBI in more than 1000 children. We have 339 
evaluated children irrespective of age, past medical history or clinical syndrome, and 340 
obtained comparable discrimination to other studies with more restrictive inclusion criteria. 341 
In common with other recent data,2, 16 we have demonstrated the value of combining clinical 342 
and biomarker variables.  343 
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This is the first broad external validation of the published multivariable model by Nijman et 344 
al. The model discriminated well, but was poorly calibrated. Specifically, there was a 345 
problem of calibration in the large – the model predicted too few cases in our population. 346 
Correlation between model predictions and observed cases suggested the overall structure of 347 
the model was appropriate to our dataset however and our approach of re-estimating the 348 
model coefficients resulted in a well-calibrated model. 349 
 350 
Limitations: 351 
This is a single centre study, and whilst we have performed internal validation of our derived 352 
model, external validity would require demonstration in an alternative setting. We have 353 
grouped ‘other SBI’ into a single outcome category. It would be preferable to model 354 
outcomes such as septicaemia and meningitis separately, but the infrequency of these 355 
outcomes makes this challenging. A pragmatic response is to advocate further diagnostic 356 
testing (including urgent urine or CSF microscopy) in children considered at high risk of 357 
‘other SBIs’. 358 
Diagnostic studies with imperfect reference standards require a pragmatic approach to 359 
determine outcomes. An established approach to this is to use pre-defined composite 360 
reference standards as we have done. The universal application of respiratory viral assays 361 
may have yielded additional evidence upon which to base classification but such testing was 362 
undertaken at the discretion of the clinical team, and not applied systematically. Our use of a 363 
radiological diagnosis of ‘pneumonia’, despite its limitations, is common in this setting.15, 33 364 
We included a category of ‘probable SBI’ to account for the lack of sensitivity of 365 
conventional diagnostic testing in children. This category accounted for only a small number 366 
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of cases (8), and was defined in advance. By establishing clear criteria for each outcome 367 
diagnosis, we have sought to minimise verification bias.  368 
We studied children already considered at risk of SBI, in whom the clinical team had initiated 369 
further investigation. This unmeasured risk evaluation limits the external validity of our 370 
findings. The proportion of SBI (24%) is significantly higher than that observed in all febrile 371 
children in the ED and we agree with previous authors who have stressed the importance of  372 
diagnostics research in low-risk populations (such as all children attending the ED, or 373 
primary care).18 Almost 80% of our sample were admitted to hospital and received 374 
antibiotics, including 60% of those who did not have SBI. Decision-making based on a low-375 
risk threshold of 5% may reduce admissions and antibiotic use but does not (by definition) 376 
eliminate risk. Clinicians would need to  combine risk evaluation with appropriate safety-377 
netting.  378 
Comparison with published studies 379 
Our finding that clinical variables such as hypoxia, abnormal respiratory findings, irritability 380 
and dehydration increase the probability of SBI is consistent with similar studies.2, 13, 16  We 381 
failed to demonstrate the value of more subjective assessments, such as ‘ill appearance’, and 382 
‘parental concern’, though for each there was a significant problem of missing data.  383 
Next steps: 384 
Our results support a growing body of research to suggest that risk prediction models 385 
improve the identification of SBI in the children’s ED. Such models have yet to translate into 386 
improved clinical decision-making. Two recent impact studies challenge the assumption that 387 
accurate risk prediction will necessarily improve decision-making. In the first, the use of the 388 
‘Lab Score’ - a decision rule combining CRP, PCT and urinalysis - failed to reduce antibiotic 389 
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prescriptions in children in the ED.34 A second evaluated the use of the Nijman risk 390 
prediction model to guide decisions, and no impact on antibiotic prescribing, or hospital 391 
admission was observed35. 392 
Future impact studies need to evaluate the behaviours associated with decision-making. This 393 
has been of considerable importance in evaluating interventions to rationalise antibiotic 394 
prescribing36. In order to translate estimates of risk into safe clinical decisions and improve 395 
the management of children in the ED, it will be necessary to involve clinicians and families . 396 
The risk thresholds we have proposed are not yet established in the context of SBI in the 397 
children’s ED, and more work is necessary to determine whether they, and the clinical 398 
decisions they guide, are appropriate. 399 
 400 
CONCLUSION 401 
A diagnostic model combining clinical and biomarker variables discriminated well between 402 
pneumonia, other SBIs and no SBI in febrile children of all ages in the ED. External 403 
validation of a previously derived risk model yielded encouraging diagnostic accuracy and 404 
was improved by the addition of PCT and Resistin. Future work should establish the value of 405 
decision rules based upon risk prediction models in robust impact studies. Such studies must 406 
address the complex behaviours associated with clinical decisions in order to yield clinical 407 
benefit.  408 
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 Overall 
n=1101 
Pneumonia 
n=108 
Other SBI 
n=156 
No SBI 
n=837 
Demographics Median IQR Median IQR Median IQR Median IQR 
Age 2.39 0.88-5.73 3.51† 1.60-6.29 2.28 0.43-7.54 2.21 0.92-5.35 
 Proportion 95%CI Proportion 95%CI Median IQR Proportion 95%CI 
Male sex 0.55 0.52-0.58 0.48 0.39-0.57 0.59 0.51-0.66 0.56 0.52-0.59 
PMH 0.31 0.28-0.34 0.47† 0.38-0.57 0.26 0.19-0.33 0.30 0.27-0.33 
Clinical variables Median IQR Median IQR Median IQR Median IQR 
Temperature 37.8 37.0-38.6 37.9* 37.1-38.9 38.0* 37.2-38.8 37.7 36.9-38.6 
Heart Rate 140 121-166 147* 132-170 148* 122-175 139 120-163 
Respiratory Rate 30 24-38 38† 28-48 30 24-38 28 24-36 
Biomarkers Median IQR Median IQR Median IQR Median IQR 
CRP / mg/l 19.6 5.8-54.0 49.0† 21.1-119 68.3† 28.9-137 14.3 4.0-36.5 
WCC / x109/l 11.5 7.9-15.8 11.8* 8.4-18.5 15.0† 10.9-20.5 10.8 7.7-14.7 
Neutrophils / x109/l 6.9 3.8-10.8 8.0† 4.8-13.4 10.0† 5.9-14.8 6.2 3.4-9.7 
NGAL / ng/l 77.1 52.5-121 92.1† 65.9-162 120† 74.4-170 69.7 49.5-103 
PCT / µg/l 0.23 0.10-0.83 0.49† 0.12-2.85 1.10† 0.15-5.85 0.18 0.09-0.53 
Resistin / ng/l 40.3 21.1-73.4 67.3† 31.4-107 60.6† 29.7-113 35.7 19.8-64.3 
Outcomes Median IQR Median IQR Median IQR Median IQR 
Length of stay/ days 2 0-3 3† 2-6 4.5† 2-7 1 0-2 
 n (%) 95%CI n (%) 95%CI n (%) 95%CI n (%) 95%CI 
Antibiotic use 
Hospital admission 
PICU 
855 (78) 
844 (77) 
19 (1.73) 
75-80 
74-79 
1.11-2.68 
108† (100) 
102† (94) 
5* (4.63) 
96-100 
88-98 
2.00-10.4 
156† (100) 
148† (95) 
10*(6.41) 
97-100 
90-98 
3.52-11.4 
509 (61) 
516 (62) 
4 (0.48) 
57-64 
58-65 
0.19-1.22 
Mortality 1 (0.09) 0.01-0.51 0 0-3.40 1 (0.65) 0.12-3.55 0 0-0.46 
Table 1: Characteristics of study subjects. IQR – interquartile range. Statistical comparisons between Pneumonia, or Other SBI and No SBI. 
Continuous data were compared by means of the Kruskal Wallis test, proportions were compared by means of the Pearson’s Chi squared 
statistic. Rare events such as admission to PICU or death were compared by means of a Monte Carlo simulation. †p<0.001 *p<0.05
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Updated Nijman model: Pneumonia 
 Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI PLR 95% CI NLR 95% CI 
2.5% 0.93 (0.86 - 0.97) 0.51 (0.47 - 0.55) 0.20 (0.16 - 0.24) 0.98 (0.96 - 0.99) 1.91 (1.75 - 2.08) 0.14 (0.07 - 0.28) 
5% 0.89 (0.81 - 0.94) 0.70 (0.67 - 0.73) 0.28 (0.23 - 0.33) 0.98 (0.97 - 0.99) 2.98 (2.63 - 3.37) 0.16 (0.09 - 0.27) 
10% 0.81 (0.79 - 0.88) 0.82 (0.79 - 0.84) 0.36 (0.30 - 0.43) 0.97 (0.95 - 0.98) 4.41 (3.72 - 5.23) 0.24 (0.16 - 0.35) 
20% 0.69 (0.60 - 0.78) 0.89 (0.87 - 0.91) 0.45 (0.38 - 0.53) 0.96 (0.94 - 0.97) 6.46 (5.12 - 8.14) 0.34 (0.26 - 0.46) 
30% 0.60 (0.92 - 0.96) 0.94 (0.92 - 0.96) 0.58 (0.48 - 0.67) 0.95 (0.93 - 0.96) 10.5 (7.66 -14.4) 0.42 (0.33 - 0.53) 
Other SBI 
2.5% 0.99 (0.96 - 1.0) 0.09 (0.07 - 0.11) 0.17 (0.15 - 0.19) 0.99 (0.93 - 1.00) 1.09 (1.06 - 1.12) 0.07 (0.01 - 0.50) 
5% 0.97 (0.93 - 0.99) 0.24 (0.21 - 0.27) 0.19 (0.17 - 0.22) 0.98 (0.95 - 0.99) 1.28 (1.22 - 1.34) 0.13 (0.06 - 0.31) 
10% 0.83 (0.77 - 0.89) 0.58 (0.55 - 0.62) 0.27 (0.23 - 0.31) 0.95 (0.93 - 0.97) 1.99 (1.79 - 2.21) 0.29 (0.20 - 0.41) 
20% 0.56 (0.48 - 0.64) 0.89 (0.87 - 0.91) 0.49 (0.41 - 0.56) 0.92 (0.90 - 0.93) 5.13 (4.04 - 6.50) 0.49 (0.41 - 0.59) 
30% 0.40 (0.32 - 0.48) 0.95 (0.94 - 0.97) 0.61 (0.51 - 0.70) 0.89 (0.87 - 0.91) 8.31 (5.80 - 11.9) 0.63 (0.56 - 0.72) 
Extended Nijman model (including PCT and Resistin): Pneumonia 
2.5% 0.94 (0.87 - 0.97) 0.52 (0.49 - 0.56) 0.20 (0.17 - 0.24) 0.98 (0.97 - 0.99) 1.96 (1.79 - 2.13) 0.12 (0.06 - 0.25) 
5% 0.92 (0.85 - 0.96) 0.69 (0.66 - 0.72) 0.28 (0.23 - 0.33) 0.98 (0.97 - 0.99) 2.96 (2.64 - 3.33) 0.12 (0.06 - 0.23) 
10% 0.85 (0.77 - 0.91) 0.82 (0.79 - 0.84) 0.38 (0.31 - 0.44) 0.98 (0.96 - 0.99) 4.66 (3.96 - 5.49) 0.18 (0.12 - 0.29) 
20% 0.70 (0.61 - 0.79) 0.89 (0.87 - 0.91) 0.46 (0.39 - 0.54) 0.96 (0.94 - 0.97) 6.69 (5.30 - 8.44) 0.33 (0.25 - 0.44) 
30% 0.62 (0.52 - 0.71) 0.94 (0.92 - 0.95) 0.56 (0.47 - 0.65) 0.95 (0.93 - 0.96) 9.99 (7.38 - 13.5) 0.4 (0.32 - 0.52) 
Other SBI 
2.5% 0.97 (0.94 - 0.99) 0.18 (0.15 - 0.20) 0.18 (0.16 - 0.21) 0.97 (0.93 - 0.99) 1.18 (1.14 - 1.23) 0.15 (0.05 - 0.39) 
5% 0.92 (0.86 - 0.95) 0.40 (0.37 - 0.44) 0.22 (0.19 - 0.26) 0.96 (0.94 - 0.98) 1.54 (1.43 - 1.65) 0.21 (0.12 - 0.35) 
10% 0.85 (0.79 - 0.90) 0.61 (0.58 - 0.65) 0.29 (0.25 -0.34) 0.96 (0.94 - 0.97) 2.21 (1.98 - 2.46) 0.24 (0.16 - 0.35) 
20% 0.70 (0.62 - 0.77) 0.86 (0.83 - 0.88) 0.48 (0.41 - 0.55) 0.94 (0.92 - 0.95) 4.96 (4.07 - 6.03) 0.35 (0.28 - 0.45) 
30% 0.53 (0.45 - 0.61) 0.94 (0.92 - 0.95) 0.61 (0.52 - 0.69) 0.91 (0.89 - 0.93) 8.40 (6.23 - 11.3) 0.50 (0.42 - 0.59) 
Table 2: Performance characteristics of the updated (top) and the extended Nijman models (bottom) including the biomarkers Procalcitonin and 
Resistin (bottom) PPV: positive predictive value, NPV: negative predictive value, PLR: positive likelihood ratio, NLR: negative likelihood ratio. 
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Outcome 
category 
Updated Extended 
n Rule-
out 
Inter-
mediate 
Rule-in Rule-
out 
Inter- 
mediate 
Rule-in 
Pneu Other Pneu Other 
No SBI 269 355 76 137 300 352 74 111 837 
Pneumonia 6 19 70 13 5 16 71 16 108 
Other SBI 13 29 7 107 9 33 7 107 156 
Total 288 403 153 257 314 401 152 234 1101 
Table 3: Outcomes according to risk classification for the updated and extended models. SBI 
was considered ‘ruled-out’ if the predicted probabilities of both pneumonia (“Pneu”) and 
other SBI (“Other”) were <5%, while SBI was considered ‘ruled-in’ if the probability of 
either outcome was >20%. All other subjects were considered to be at intermediate risk. 
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Figure legends: 
Figure 1: Flow diagram of the study. PID: Primary immunodeficiency. ED: Emergency 
Department. SBI: Serious Bacterial Infection. Excluded children with a ‘clinical reference 
standard’ are explained in the text. 
Figure 2: Parametric nominal calibration plot of predicted risks and observed outcomes in the 
validation set. 
Figure 3: Parametric nominal calibration plot of the original Nijman model on external 
validation. 
Figure 4: Parametric nominal calibration plot of the Nijman model with co-efficients re-fitted 
to the validation dataset. 
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 Derivation group (n=532) Validation group (n=569) 
No SBI 
(401) 
Pneu (63) 
Other SBI 
(68) 
No SBI 
(436) 
Pneu (45) 
Other SBI 
(88) 
FBC 391 (98) 62 (98) 68 (100) 427 (98) 45 (100) 87 (99) 
Urinalysis 99 (25) 10 (16) 17 (25) 97 (22) 7 (16) 25 (28) 
Blood 
culture 
257 (64) 54 (86) 56 (82) 280 (64) 42 (93) 77 (88) 
CXR 168 (42) 61 (97) 24 (35) 195 (45) 44 (98) 38 (43) 
Supplementary Table 1: Number (%) of diagnostic tests performed in each group. FBC: Full 
blood count, CXR: Chest X-ray 
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Diagnosis Criteria 
Pneumonia Respiratory symptoms and signs and focal consolidation on X-ray 
reported by a paediatric radiologist. 
Other SBI  
 Bacteraemia Identification of a significant bacterial pathogen in blood using culture 
or molecular methods. 
 Urinary tract 
 infection 
Growth of a single bacterial urinary tract pathogen at ≥105 colony-
forming units/ml in a normally sterile urine sample in the context of 
clinical signs of systemic involvement. 
 Meningitis Identification of a bacterial pathogen in CSF using culture or molecular 
methods, or clinical meningitis plus a cerebrospinal fluid 
polymorphonuclear leucocytosis in the absence of an alternative 
aetiological diagnosis. 
 Osteomyelitis Clinical signs, and radiological confirmation or identification of a 
pathogen in the bloodstream. 
 Septic 
 arthritis 
Isolation of a bacterial pathogen from a joint. 
 Probable SBI Prolonged admission, and administration of intravenous antibiotics 
beyond 72h despite negative culture results. 
Supplementary Table 2: Pre-defined criteria for the diagnosis of SBI14, 15, 25 
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Variable Observations 
Missing 
n % 
Neck stiffness 652 449 40.8 
Normal air entry 1069 32 2.9 
Chest clear 1069 32 2.9 
Bulging fontanelle 246 855 77.7 
Rash 1009 92 8.4 
Abdominal pain 306 795 72.2 
Parental concern 159 942 85.6 
History of myalgia 151 950 86.3 
Irritability 256 845 76.7 
Abnormal ENT signs 921 180 16.3 
Heart rate 1058 43 3.9 
History of diarrhoea 899 202 18.3 
Respiratory rate 907 194 17.6 
Duration of fever (day) 1101 0 0.0 
Temperature 1092 9 0.8 
Prolonged Capillary Refill (>2s) 909 192 17.4 
History of dysuria 270 831 75.5 
Dehydration 480 621 56.4 
Pallor 469 632 57.4 
Comorbidity 1101 0 0.0 
History of drowsiness 295 806 73.2 
Prior antibiotics 1097 4 0.4 
Wheeze 1074 27 2.5 
Ill appearance 108 993 90.2 
History of chest pain 118 983 89.3 
Chest crackles 1071 30 2.7 
History of cough 847 254 23.1 
Hypoxia (Sats <92%) 963 138 12.5 
Decreased Breath Sounds 1068 33 3.0 
Increased Work of Breathing 1071 30 2.7 
Supplementary Table 3: Proportion of missing data for each observed clinical variable.  
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Characteristics 
Derivation Validation 
Erasmus (n=1750) Haga-Juliana (n=967) Liverpool (n=1101) 
Median age/years (IQR) 1.8 (0.9-3.7) 1.5 (0.7-3.2) 2.4 (0.9-5.7) 
Male sex 0.57 0.55 0.55 
Median (IQR) duration of 
fever (days) 
n=1185 n=807 n=1052 
2 (1-3) 2 (1-3) 2 (0-3) 
Median temperature/°C 
(IQR) 
n=1699 n=967 n=1092 
39.0 (38.3-39.7) 38.8 (38.3-39.4) 37.8 (37.0-38.6) 
Median heart rate (IQR) 
n=914 n=473 n=1058 
140 (120-160) 156 (140-172) 140 (121-166) 
Median respiratory rate 
(IQR) 
n=819 n=183 n=907 
36 (28-48) 48 (40-60) 30 (24-38) 
Oxygen saturations <94% 
n=914 n=473 n=963 
41 43 82 
Cap refill time >3s 
n=914 n=473 n=909 
96 9 40 
Increased work of 
breathing 
n=914 n=473 n=1071 
97 108 218 
Ill appearance 
n=914 n=473 n=108 
520 317 64 
Median CRP (IQR) 
n=780 n=317 n=1072 
21 (7-54) 22 (7-56) 20 (6-54) 
Outcomes    
SBI/ n (%) 
Pneumonia 
UTI 
Septicaemia/meningitis 
Other 
222 (13) 
105 (6) 
50 (3) 
21 (1) 
46 (3) 
119 (12) 
66 (7) 
38 (4) 
1 (0) 
14 (1) 
264 (24) 
108 (10) 
58 (5) 
49 (4) 
49 (4)  
Supplementary table 4: Comparison of characteristics of study participants used in the derivation of 
the Nijman risk prediction model, and the Liverpool validation group 
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Biomarkers n 
Pneumonia Other SBI 
OR LCI UCI OR LCI UCI 
Procalcitonin 1034 1.22 1.15 1.29 1.23 1.16 1.30 
Neutrophils 1059 1.09 1.06 1.13 1.12 1.09 1.15 
WCC 1059 1.05 1.02 1.08 1.08 1.06 1.11 
CRP 1072 1.02 1.01 1.02 1.02 1.02 1.02 
Resistin 1045 1.01 1.00 1.01 1.01 1.01 1.01 
NGAL 1046 1.00 1.00 1.01 1.01 1.00 1.01 
Blood glucose 123 0.78 0.54 1.12 1.03 0.89 1.20 
Lactate 167 0.67 0.42 1.09 1.12 0.84 1.50 
Supplementary Table 5: Odds ratios of biomarker variables significantly associated with 
pneumonia and other SBI in univariate multinomial regression analysis. OR: Odds ratio. LCI: 
Lower (95%) confidence interval. UCI: Upper (95%) confidence interval. 
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Supplementary table 6: Summary output of the derived polynomial models for the diagnosis 
of pneumonia and other SBIs. Est: Estimate of the regression co-efficient. 
  
 
Pneumonia Other SBI 
Est OR LCI UCI Est OR LCI UCI 
(Intercept) -2.516 0.081 0.025 0.260 -2.779 0.062 0.016 0.239 
CRP / mg/l (<30) 0.025 1.025 0.990 1.060 0.045 1.046 1.011 1.081 
CRP / mg/l (>30) 0.010 1.010 1.003 1.018 0.012 1.012 1.005 1.019 
Respiratory rate 0.047 1.048 1.021 1.076 0.009 1.009 0.980 1.039 
PCT / µg/l 0.173 1.189 1.079 1.310 0.168 1.183 1.074 1.303 
Normal air entry -2.387 0.092 0.046 0.182 0.240 1.271 0.514 3.142 
Resistin / ng/ml 0.003 1.003 0.999 1.008 0.004 1.004 1.000 1.007 
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Outcome 
diagnosis 
n 
Updated model Extended model 
No SBI Pneumonia Other SBI No SBI Pneumonia Other SBI 
No SBI 837 801 18 18 807 17 13 
Pneumonia 108 61 44 3 58 45 5 
Other SBI 156 106 2 48 89 2 65 
Supplementary table 7: Observed and predicted outcomes as determined by the highest risk 
category predicted by the updated and extended multinomial models. 
 



